Effect of high-dose DPP-4 inhibitor or single-dose rapid-acting insulin on glycemic control in type 2 diabetic patients treated with regular-dose DPP-4 inhibitor and long-acting insulin

Effect of high-dose DPP-4 inhibitor or single-dose rapid-acting insulin on glycemic control in type 2 diabetic patients treated with regular-dose DPP-4 inhibitor and long-acting insulin - High-dose DPP-4 inhibitor versus single-dose rapid-acting insulin in BOT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010211

Enrollment

Registered

2013-03-26

Start date

2013-03-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

To increase the dose of sitagliptin to 100 mg per day To initiate the single-dose administration of insulin glulisine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients under the combination therapy of sitagliptin and long-acting insulin

Exclusion criteria

Exclusion criteria: - severe hepatic, renal, and/or cardiac disease - hypersensitivity to the drug using in the study - pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
Glycemic control assessed with self-monitoring of blood glucose	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026